linjc16/ctgov huggingface dataset:
Mediastinal Staging of Lung Cancer With EBUS-TBNA and EUS-B-FNA

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to find a role of EUS-B-FNA in the mediastinal staging of potentially operable lung cancer. The investigators perform EBUS-TBNA and EUS-B-FNA on potentially operable lung cancer patients. The investigators perform EBUS(+/- TBNA) and EUS-B (ultrasonographic examination through the esophagus) on all subjects. EUS-B-FNA will be performed on inaccessible nodes or difficult nodes to be sampled by EBUS-TBNA. Additional diagnostic values of EUS-B-FNA as compared to EBUS-TBNA alone will be estimated.

Official Title
-----------------
Minimally Invasive Mediastinal Staging of Potentially Operable Lung Cancer With Endobronchial Ultrasound Guided Transbronchial Needle Aspiration(EBUS-TBNA) and Transesophageal Aspiration Using Ultrasonic Bronchoscope (EUS-B-FNA)

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Procedure: EBUS-TBNA, EUS-B-FNA (EUS-FNA with bronchoscope)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically confirmed or strongly suspected potentially operable non-small cell lung cancer (NSCLC) Potentially operable patients Exclusion Criteria: After staging work-up for NSCLC, including bronchoscopy,CT of the chest and upper abdomen, integrated PET/CT and brain MRI (and/or bone scan) M1 disease Inoperable T4 disease Mediastinal infiltration or extranodal invasion of the mediastinal lymph node visible on chest CT. Confirmed supraclavicular lymph node metastasis Pancoast tumors Medically inoperable patients Contraindications for bronchoscopy
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: EBUS-TBNA, EUS-B-FNA (EUS-FNA with bronchoscope)|EBUS-TBNA is a bronchoscopic diagnostic method that enables real time aspiration of paratracheal and peribronchial lesions. EUS-FNA is a procedure to obtain samples through the esophagus under real-time ultrasound guidance. In this study, EUS-FNA will be applied using a ultrasonic bronchoscope (EUS-B-FNA).|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The diagnostic values of EBUS-TBNA plus EUS-B-FNA as compared to EBUS-TBNA alone |  | June 2009 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Proportion and the location of lymph nodes accessible by EBUS-TBNA and EUS-B-FNA. |  | June 2009 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
staging, Endobronchial ultrasound, Endoscopic ultrasound
Smoking While on Transdermal Nicotine Replacement Therapy: Effects on Craving and Cessation

Study Overview
=================
Brief Summary
-----------------
Smoking while on nicotine patches will help subjects to reduce their expired carbon monoxide levels from the levels they were before they started using the patch. Subjects will also decrease their daily consumption of cigarettes.

Detailed Description
-----------------
Subjects who smoke while on an individually dosed tNRT will reduce their expired carbon monoxide levels from pre- to post-treatment conditions. They will also decrease their daily consumption of cigarettes.

Official Title
-----------------
Smoking While on Transdermal Nicotine Replacement Therapy: Effects on Craving and Cessation

Conditions
-----------------
Nicotine Dependence

Intervention / Treatment
-----------------
* Drug: Nicoderm


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: at least 19 years of age male or female have intention to quit smoking within the next 6 months smoke 10 or more cigarettes per day Exclusion Criteria: Pregnant or not using an adequate enough method of birth control to ensure that they are not at risk of becoming pregnant breastfeeding have any generalized skin disorders are in an immediate post-myocardial infarction period or have life-threatening arrhythmias, have severe or worsening angina pectoris or have had a recent cerebral vascular accident are using additional nicotine replacement therapies or any other smoking cessation pharmacotherapy any clinically significant ECG abnormalities any known hypersensitivity to components of the transdermal system

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: single open-label treatment arm<br>Adult smokers willing to quit were treated with escalating doses of transdermal nicotine patch (Nicoderm) and brief counselling if they continued to smoke over a 9-week treatment period. | Drug: Nicoderm<br> <br> * Other names: nicotine patch;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Carbon Monoxide Levels | Expired Co levels were measured to confirm smoking status | measured at week 10 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Smoking Cessation | self reported # cigarettes per day | Week 10 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
nicotine dependence,, transdermal nicotine patch,, smoking while receiving nicotine replacement,, comorbidities
Dendritic Cell Vaccination in Patients With Advanced Colorectal Cancer

Study Overview
=================
Brief Summary
-----------------
Dendritic cells loaded with tumor antigens induce cytotoxic T-cells which have been proved capable of killing both melanoma and breast cancer cells. Melanoma and colorectal cancer cells express some common antigens. Hence it is possible to use melanoma lysate to load the dendritic cells with tumor antigens similar to the antigens expressed by the patients' colorectal cancer cells. The patient receives 10 vaccinations with 14 days between each. The parameters for effect are changes in tumor/metastasis size measured with computed tomography (CT), decrease in serum concentration of carcinoembryonic antigen (CEA), performance status measured by the World Health Organization (WHO) criteria, and Quality of Life.

Official Title
-----------------
Vaccination With Autologous Dendritic Cells Pulsed With Allogenous Melanoma Lysate (MelCancerVac) for Treatment of Patients With Advanced Colorectal Cancer

Conditions
-----------------
Colorectal Neoplasms

Intervention / Treatment
-----------------
* Biological: MelCancerVac


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Verified cancer of colon or rectum No chemo- or radiation therapy in 6 weeks Performance status 0, 1, or 2 (WHO criteria) Adequate function of the kidneys, liver, lungs, and heart Adequate function of the hematopoietic system and the coagulation system Negative pregnancy test and adequate birth control for fertile women Exclusion Criteria: Pregnancy Uncontrolled infection

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: MelCancerVac|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dendritic cells, antigens, neoplasm
MSG and Gastrointestinal Motility

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to clarify the physiological function of sodium glutamate by measuring its effect on upper GI motility ( gastric emptying).

Detailed Description
-----------------
Amino acids such as monosodium glutamate are known to stimulate both endocrine and exocrine secretion. In addition, there is a report that oral intake of glutamate evokes the activation of vagal afferent nerves in the rat. Thus, such amino acids are thought to be influential in the process of digestion and absorption. . To investigate the effect of monosodium glutamate on gastrointestinal motility, we planned a single-blind randomized study. The participants will take either monosodium glutamate or sodium chloride before the first examination of upper GI motility and the other agent before the second examination. The order of intake will be randomized by the envelope method.

Official Title
-----------------
Effect of Monosodium Glutamate on Upper Gastrointestinal Tract Motility

Conditions
-----------------
Gastroesophageal Reflux

Intervention / Treatment
-----------------
* Dietary Supplement: Monosodium glutamate
* Dietary Supplement: Sodium chloride


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy subjects Must not have digestive symptoms Must not eat within six hours of study participation Exclusion Criteria: Regular medications for the gastrointestinal tract Previous Helicobacter pylori infection Previous abdominal surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: MSG first<br> | Dietary Supplement: Monosodium glutamate<br>* Oral intake of 2.0 g of monosodium glutamate on the examination day and 0.6 g of sodium chloride on the other examination day.<br>|
| Placebo Comparator: NaCl first<br> | Dietary Supplement: Sodium chloride<br>* Oral intake of 0.6 g of sodium chloride on the examination day and 2.0 g of monosodium glutamate on the other examination day.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gastric emptying | half emptying time | 0-5 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Gastrointestinal motility, Gastroesophageal reflux, Gastric emptying, Sodium glutamate, Lower esophageal sphincter
B2 Adrenergic Receptor Gene Polymorphism in Bronchial Asthma

Study Overview
=================
Brief Summary
-----------------
The b2-adrenoceptor (b2AR) mediates the physiological responses in the airway, which include bronchodilation, bronchoprotection. The b2-adrenoceptor (b2AR) mediates the physiological responses in the airway, which include bronchodilation, bronchoprotection, Enhanced mucociliary clearance. The b2AR gene is located on chromosome 5q31-q32, a region that is genetically linked to asthma and related phenotypes. There are three best known polymorphisms in the coding region of the b2AR gene that can modulate the function of the receptor.

Detailed Description
-----------------
Asthma is a complex disease and has a strong genetic component in its pathogenesis. So far, considerable efforts have been made to evaluate the association between genetic variants and asthma risk, and numerous genes have been identified as asthma Reporting Items susceptible genes. The b2-adrenoceptor (b2AR) mediates the physiological responses in the airway, which include bronchodilation, bronchoprotection. The b2-adrenoceptor (b2AR) mediates the physiological responses in the airway, which include bronchodilation, bronchoprotection, Enhanced mucociliary clearance. The b2AR gene is located on chromosome 5q31-q32, a region that is genetically linked to asthma and related phenotypes. There are three best known polymorphisms in the coding region of the b2AR gene that can modulate the function of the receptor.

Official Title
-----------------
B2adrenergic Receptor Gene Polymorphism in Bronchial Asthma: Relation to Disease Severity and Control

Conditions
-----------------
Gene Abnormality, Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients diagnosed as asthma according to GINA guideline 2016. Allergic asthma Exclusion Criteria: pneumonia chronic cardiac, hepatic and renal diseases pregnancy and lactation malignancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To measure number of patient with homozygous and heterozygous B2AD gene polymorphisms with focus on Arg/Gly16 and Gln/Glu27 polymorphism | study of prevalence homozygote and heterozygote patients | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patient with b2AR gene polymorphisms in different asthma severity and different response of treatment of asthma ( Arg/Gly16 and Gln/Glu27 polymorphism) | correlation between polymorphism and pulmonary function test and level of disease control | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma, B2 adrenergic receptors, Polymorphism
Exercise Intervention and Running Biomechanics in Older Adults

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to understand the effects of muscle strengthening and stretching exercise intervention on isometric muscle strength, joint flexibility and running biomechanical patterns in older recreational runners. To do so, the subjects will be assessed before and after they engage in a 8-week exercise intervention program.

Official Title
-----------------
Changes in Running Gait Biomechanics Following an Intervention Program in Older Runners

Conditions
-----------------
Aging, Physical Activity

Intervention / Treatment
-----------------
* Other: Muscle strengthening exercises
* Other: Muscle stretching exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: no injuries of the lower extremity within 3 months prior to participation running recreationally 2-3 times/week familiar and comfortable with treadmill running in good health upon entry into the study no use of orthotics in the shoe Exclusion Criteria: lower extremity injury within the last 3 months surgery to the lower extremity within the last 8 months head injury/vestibular disorder within the last 6 months inability to speak or read English.

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Strengthening Exercises<br>Recreational older runners recruited from local community | Other: Muscle strengthening exercises<br>* The group will perform 8-week home based muscle strengthening exercises with 8 weekly supervised sessions which will be conducted by a rehabilitation specialist.<br>|
| Experimental: Stretching Exercises<br>Recreational older runners recruited from local community | Other: Muscle stretching exercise<br>* The group will perform 8 week home based exercise intervention with 8 weekly supervised sessions which will be conducted by a rehabilitation specialist<br>|
| No Intervention: Control Group<br>Recreational older runners recruited from local community | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes from baseline of biomechanical movement patterns | Biomechanical measurements (kinematics and kinetics) will be taken at baseline and at 8 weeks of intervention. | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in isometric muscle strength and joint flexibility | Measurements of isometric muscle strength and joint flexibility will be taken at baseline and at 8 weeks of intervention program. | 8 weeks |
Posterior Approach to Total Shoulder Arthroplasty

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate preoperative objective measurements and operative objective measurements to determine if there is any effect to postoperative outcomes. Patients who were 18 years old or greater at the time of surgery were followed clinically and radiographically to determine best practice and optimal treatment and technique, risk and rate of complication, and postoperative outcomes.

Official Title
-----------------
Posterior Approach to Total Shoulder Arthroplasty: A Data Analysis on Patients Undergoing the Posterior Approach to Total Shoulder Arthroplasty

Conditions
-----------------
Total Shoulder Arthroplasty, Osteo Arthritis Shoulders

Intervention / Treatment
-----------------
* Procedure: posterior approach to total shoulder arthroplasty


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: English speaking >18 years of age Underwent posterior approach to total shoulder arthroplasty by Dr. Michael Greiwe at St. Elizabeth Healthcare Exclusion Criteria: Non-English speaking <18 years of age Loose bone in the anterior recess of the shoulder Severe arthritis with significant bony deformity

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: posterior approach to total shoulder arthroplasty|The posterior approach to total shoulder arthroplasty approaches the patient from the back of the shoulder and spares the rotator cuff.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| recovery | American shoulder and elbow score (ASES) with a range from 0-100, with 0 being worst outcome and 100 being best outcome | preoperative to 6 months postoperatively | 
| recovery | Simple Shoulder Test score (SST) with a range from 0-12 with 12 being the best score and 0 being the worst score. | preoperative to 6 months postoperatively | 
| recovery | range of motion | preoperative to 6 months postoperatively | 
| complications | percent of complications | 6 months postoperative |
Isolation, Characterization and Evaluation of the Potential of TissuE-resideNt cElls From Waste Musculoskeletal and Associated Connective Tissues

Study Overview
=================
Brief Summary
-----------------
The general purpose of this study is characterization of tissue-resident cells derived from different musculoskeletal and/or associated connective tissues (such as cartilage, synovial membrane, synovial fluid, bone, adipose tissue and tendons), in order to identify new strategies for the treatment of degenerative and inflammatory musculoskeletal disorders. Cells isolated from different tissue sources will be compared with each other by phenotypic and functional characterization, following culture and treatment with inflammatory elements, drugs and orthobiologics. Moreover, with the aim to assess predictive markers of therapeutic success, a correlation study of the content and properties of the cells isolated from different types of tissue with the clinical profile of the enrolled patients will be conducted.

Official Title
-----------------
Isolation, Characterization and Evaluation of the Potential of TissuE-resideNt cElls From Waste Musculoskeletal and Associated Connective Tissues

Conditions
-----------------
Musculoskeletal Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: males and females 18 years old patients undergoing elective surgery at IRCCS Istituto Ortopedico Galeazzi among which joint surgery (including hip or knee replacement), or anterior cruciate ligament (ACL) reconstruction or rotator cuff repair Exclusion Criteria: age < 18 years old patients unable to sign the Informed Consent positivity to virological test (HIV, HCV, HBV, TPHA)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation beetween patients' age and cell yield | The primary outcome of the study will be to identify possible correlations between the cellular yields and patients age. The data from different tissue sources will be analyzed to assess whether the changes are tissue-specific. | 5 years |